glp-1 and dpp4 degrade the GLP1 incretion, which leads to suppression of the Frontiers | DPP-4 Inhibitors as

Mitopure activates a mitochondrial quality control process known as mitophagy

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus

Ozempic, another semaglutide product, saw a 30% increase, while even the older Victoza (liraglutide) grew by 21%, driven by a 113% surge in North American demand

Understanding these potential connections helps patients and healthcare professionals distinguish between benign changes and those requiring investigation

GLP-1 receptor agonists seem to have the unique ability to reduce these effects without completely blocking dopamine release

doi:10.2147/dddt.s531778 Hanks J